普伐他汀在代谢综合征患者中的应用

Efficacy and safety of pravastatin in patients with metabolic syndrome

目的探讨普伐他汀对集聚了多种心血管病危险因子的代谢综合征患者的干预作用。方法选择代谢综合征患者62例，在改善生活方式治疗的同时随机分为普伐他汀治疗组32例及对照组30例。检测治疗前及治疗后12周的血脂、血压、尿白蛋白排泄率（UAER）、体质指数（BMI）、空腹及餐后2h血糖（FIG、2hPG）。结果经普伐他汀20mg／d治疗12周，患者血脂异常得到改善，收缩压及舒张压分别下降4．06％、5．88％，UAER降低18．5％，与对照组比较差异有显著性（P〈0．05）；2组患者BMI、FPG及2hPG均有下降趋势，但组间比较差异元显著性（均P〉0．05）。观察期间无严重不良反应发生。结论普伐他汀可改善代谢综合征患者的血脂紊乱、高血压及微量白蛋白尿，可安全地应用于代谢综合征患者。

Objective To investigate the effect of pavastatin in treating metabolic syndrome （MS） with cardiovascular disease risk factors. Methods Sixty-two patients with MS were randomized into two groups, treatment group receiving pravastatin 20mg/day （n = 32） and control group （n = 30）. The blood pressure, lipid profile, UAER, BMI, FPG and 2hFPG were measured before and after 12-weeks treatment. Results 12 weeks treatment later abnormal blood lipid was improved in treatment group. SBP、DBP and UAER were by 4.06% significantly decreased、5.88%、18.5% respectively in pravastatin-treated group （P 〈 0.05）. But there were no significant difference between two groups in BMI、FPG and 2h PG reduction （P 〉 0.05）. Only minor side effects were observed. Conclusion Pravastatin can be safely used for treating metabolic syndrome because it can ameliorate the lipid disturbance, hypertension and microalbuminuria.